Analysis – Goldea Capital

Prospectiva Resources Commences Drilling at the São Francisco Copper-Gold Project

Written by Customer Service on August 28, 2026. Posted in Public Companies.

TORONTO, Aug. 28, 2026 (GLOBE NEWSWIRE) — Prospectiva Resources Ltd. (TSX-V: PSVA) (“Prospectiva” or the “Company”), a Brazil-focused copper and gold exploration company advancing a portfolio of 100%-owned projects in the highly-prospective Borborema Belt, is pleased to announce that its maiden diamond drilling programme at its flagship São Francisco Copper-Gold Project (“São Francisco” or the “Project”) is underway. The fully funded drill programme comprises 2,500m across 10 holes. The first hole is already complete with drilling underway at hole two. The programme is expected to be complete by November. Drill results will be released as assays are received and reviewed by the Company. Dan James, Chief Executive Officer of Prospectiva said, “We believe São Francisco has the potential to be significantly larger than the mineralised...

MoneyHero Group to Announce Second Quarter 2026 Results

Written by Customer Service on August 28, 2026. Posted in Public Companies.

HONG KONG and SINGAPORE, Aug. 28, 2026 (GLOBE NEWSWIRE) — MoneyHero Limited (Nasdaq: MNY) (“MoneyHero” or the “Company”), a leading tech- and AI-powered personal finance aggregation and comparison platform and a digital insurance brokerage provider in Greater Southeast Asia, today announced that it will release its second quarter 2026 results on Friday, September 11, 2026 before market opens and will hold a related conference call to discuss the results at 8:00 a.m. EDT (or 8:00 p.m. Hong Kong / Singapore time) on the same day. Investors and other interested parties may listen to the call by clicking on the registration link for the webcast or audio conference at: Webcast: https://edge.media-server.com/mmc/p/xwtrskosConference call: https://register-conf.media-server.com/register/BI214539fed1c440429ce5c56522b13799 The webcast replay...

Jiayin Group Inc. Reports Second Quarter 2026 Unaudited Financial Results

Written by Customer Service on August 28, 2026. Posted in Earnings Releases And Operating Results.

SHANGHAI, Aug. 28, 2026 (GLOBE NEWSWIRE) — Jiayin Group Inc. (“Jiayin” or the “Company”) (NASDAQ: JFIN), a leading fintech platform in China, today announced its unaudited financial results for the second quarter ended June 30, 2026. Second Quarter 2026 Operational and Financial Highlights:Transaction volume1 was RMB9.5 billion (US$1.4 billion), representing a decrease of 74.4% from the same period of 2025. Average borrowing amount per borrowing was RMB6,663 (US$982), representing a decrease of 18.0% from the same period of 2025. Repeat borrowing contribution2 was 73.1%, compared with 75.6% in the same period of 2025. 90 day+ delinquency ratio3 was 2.21% as of June 30, 2026. Net revenue was RMB736.9 million (US$108.6 million), representing a decrease of 60.9% from the same period of 2025. Loss from operations was RMB246.7 million...

Teva Announces Proposed Acquisition of a Novel Neuroscience Product Reinforcing Disciplined Business Development Approach Under Pivot to Growth Strategy

Written by Customer Service on August 28, 2026. Posted in Mergers And Acquisitions.

Teva Announces Proposed Acquisition of a Novel Neuroscience Product Reinforcing Disciplined Business Development Approach Under Pivot to Growth StrategyTeva Announces Proposed Acquisition of a Novel Neuroscience Product Reinforcing Disciplined Business Development Approach Under Pivot to Growth StrategyBXCL501, a novel dexmedetomidine sublingual film, is under FDA review for potential at-home (outpatient) use for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. Agreement is part of a court-supervised sale process with BioXcel Therapeutics, Inc. and remains subject to bankruptcy court approval, potential higher bids, and customary closing conditions. Transaction reflects Teva’s targeted business development approach focused on strategic fit, patient needs, and potential...

Form-8.3 APTITUDE SOFTWARE GROUP PLC – 27 08 2026 – (CGAML)

Written by Customer Service on August 28, 2026. Posted in Mergers And Acquisitions.

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION(a) Full name of discloser: CANACCORD GENUITY ASSET MANAGEMENT LIMITED (for Discretionary clients)(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree APTITUDE SOFTWARE GROUP PLC(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: APTITUDE...

Form-8.3 GOOCH & HOUSEGO PLC – 27 08 2026 – (CGWL)

Written by Customer Service on August 28, 2026. Posted in Mergers And Acquisitions.

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION(a) Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree GOOCH & HOUSEGO PLC(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e) Date position...

Form-8.3 ADVANCED MEDICAL SOLUTIONS GROUP PLC – 27 08 2026 – (CGWL)

Written by Customer Service on August 28, 2026. Posted in Mergers And Acquisitions.

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION(a) Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree ADVANCED MEDICAL SOLUTIONS GROUP PLC(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e) Date...

Cytokinetics Announces Positive Results from ACACIA-HCM Presented in Hot Line Session at the European Society of Cardiology (ESC) Congress 2026 and Published in The New England Journal of Medicine

Written by Customer Service on August 28, 2026. Posted in Public Companies.

ACACIA-HCM is the First Phase 3 Clinical Trial to Successfully Demonstrate Statistically Significant Improvements Across Both Patient-Reported and Physician-Assessed Endpoints in Non-Obstructive HCM Supplemental New Drug Application to be Submitted to FDA in Fourth Quarter Company to Host Investor Event and Webcast Today at 2:00 PM Central European Summer Time (8:00 AM Eastern Time) SOUTH SAN FRANCISCO, Calif., Aug. 28, 2026 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the primary results from ACACIA-HCM (Assessment Comparing Aficamten to Placebo on Cardiac Endpoints In Adults with Non-Obstructive HCM), the pivotal Phase 3 clinical trial of aficamten in patients with symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM) were presented in a Hot Line Session at the European Society of Cardiology...

CDT Validates Enhanced Solid-Form Properties Within Its IP Portfolio

Written by Customer Service on August 28, 2026. Posted in Public Companies.

NAPLES, Fla. and CAMBRIDGE, United Kingdom, Aug. 28, 2026 (GLOBE NEWSWIRE) — CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today announced that new solid forms and alternative crystal structures of its existing drug compounds, show enhanced physical property advantages, including improved stability, solubility, manufacturability, over existing forms of these compounds. These solid forms are patent-protected under the Company’s Substance of Matter IP and could support new formulations tailored to specific patient needs, prospectively increasing the commercial life of the underlying assets. Following implementation of Sarborg’s Signature Intelligence to identify new potential uses for CDT’s existing assets, alone or in combination with currently marketed drugs, CDT has filed patents to protect these findings. The new uses...

SSCP Lager Bidco AB (publ) – Interim report for second quarter 2026

Written by Customer Service on August 28, 2026. Posted in Earnings Releases And Operating Results.

Date: 28th of August 2026SSCP Lager BidCo AB (publ) – Interim report for the period 1 April – 30 June 2026. Today SSCP Lager Bidco AB (publ) published an interim report for the second quarter, the report can be downloaded from www.logentgroup.com or via the link below. For more information, please contact:Andrzej Kulik, CFO, telephone number: +46 738 15 67 00, andrzej.kulik@logent.se or Joel Engström, CEO, telephone number: +46 734 36 36 29, joel.engstrom@logent.se This press release was published on 28-08-2026 at 10:00 CET/CEST This information is of the type that SSCP Lager BidCo AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation, the Swedish Securities Markets Act and the Swedish Financial Instruments Trading Act. The information was submitted for publication through the agency of the contact persons set...

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals